Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.
Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.
Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.
Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.
Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.
Exscientia plc (Nasdaq: EXAI) announced the advancement of two additional discovery programmes within its collaboration with Sanofi. The company will receive $15 million in milestone payments for these achievements. Both lead compounds have met the product profile requirements to transition to the lead optimisation phase and have shown high differentiation potential for best-in-class assets.
Exscientia is eligible for over $600 million in additional milestone payments for these two programmes, as well as high-single-digit to mid-teen royalties on product sales. Three programmes in the partnership have now advanced through initial milestones, with multiple more progressing at earlier stages. The milestone payment is expected to be received in Q4 2024 and will be recognised as revenue over the collaboration duration.
Exscientia plc (Nasdaq: EXAI) announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain. The presentations focus on:
1. Combining MALT1 inhibitor EXS73565 with BTK inhibitors for enhanced efficacy in B-cell malignancies.
2. In vivo studies of EXS74539, a novel LSD1 inhibitor for acute myeloid leukemia (AML).
3. Xcellomics collaboration with the University of Oxford for rapid translation of high-throughput screening results.
Key highlights include:
- EXS73565 combined with zanubrutinib showed deeper, more durable efficacy in B-cell malignancy models.
- EXS74539 demonstrated platelet level effects in AML models.
- Identification of 12 potential pharmacodynamic biomarkers for LSD1 inhibitor activity.
- Both EXS73565 and EXS74539 are expected to enter clinical studies in early 2025.
Rallybio (Nasdaq: RLYB) presented nonclinical data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting, demonstrating ENPP1 inhibition as a potential therapeutic approach for hypophosphatasia (HPP). The study, using an early lead ENPP1 inhibitor (REV101) in a mouse model of later-onset HPP, showed promising results:
1. Oral dosing lowered PPi by 30%
2. Improved mineralization of long and vertebrate bones
3. ENPP1 inhibition was safe and well-tolerated
Rallybio and Exscientia plc (Nasdaq: EXAI) are developing an improved ENPP1 inhibitor for HPP treatment, with a development candidate expected to be nominated in Q4 2024. This approach could potentially address the unmet need in HPP patients, particularly adults.
Exscientia plc (Nasdaq: EXAI) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. David Hallett, the company's interim CEO and Chief Scientific Officer, will engage in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. EDT (12:00 p.m. BST).
The event will be accessible via a live webcast on Exscientia's website under the "Investors & Media" section at investors.exscientia.ai. For those unable to attend live, an archived replay of the webcast will remain available for approximately 30 days following the presentation.
Exscientia plc (Nasdaq: EXAI) announced key business updates and financial results for Q2 and H1 2024. Highlights include:
1. Definitive agreement to combine with Recursion Pharmaceuticals, creating a global technology-enabled drug discovery leader.
2. Acquisition of full rights to GTAEXS617 (CDK7 inhibitor), with Phase I data expected in 2H24.
3. Launch of AWS AI-powered platform to advance drug discovery.
4. Progress in LSD1 and MALT1 inhibitor programmes, on track for 2H24 IND/CTA submissions.
5. Expansion of collaborations with Sanofi, Merck KGaA, and READDI.
6. Revenue for H1 2024 was $12.3 million, up from $11.1 million in H1 2023.
7. Cash balance of $370.1 million as of June 30, 2024.
Viva Biotech's portfolio companies have made significant progress recently:
- Nerio Therapeutics, invested by Viva BioInnovator (VBI), was acquired by Boehringer Ingelheim for up to $1.3 billion.
- Apeiron Therapeutics reached an agreement with Exscientia (NASDAQ: EXAI), receiving $30 million upfront and potential royalties.
- Full-Life Technologies entered a $571.5 million licensing agreement with SK Biopharmaceuticals for its FL-091 radiopharmaceutical compound.
- Arthrosi Therapeutics dosed the first patient in its Phase 3 REDUCE 2 trial for AR882 and presented results at EULAR 2024.
- VivaVision Biotech enrolled the first subject in its VVN001 Phase III clinical trial in China for dry eye disease treatment.
Exscientia plc (Nasdaq: EXAI) has acquired full rights to the oral CDK7 inhibitor programme, including GTAEXS617, from GT Apeiron. This acquisition maximizes the potential of the precision-designed compound ahead of its Phase 1 dose escalation data readout. The ELUCIDATE Phase 1/2 trial is progressing well, with monotherapy dose escalation data expected in the second half of 2024. A combination dose escalation study for HR+/HER2- breast cancer is planned for late 2024/early 2025. Exscientia will pay GT Apeiron $10 million in cash, $10 million in equity, and single-digit royalties on potential commercialization. Despite this transaction, Exscientia's cash runway is expected to extend well into 2027.
Exscientia has announced an expansion of its collaboration with Amazon Web Services (AWS) to enhance its drug discovery platform using AI and machine learning (ML). This collaboration integrates generative AI and robotic lab automation to accelerate drug development and reduce costs.
Exscientia's platform leverages AWS technologies to design drug candidates that target specific diseases more effectively. The platform's DesignStudio uses generative AI for drug discovery, while the AutomationStudio synthesizes and tests these candidates, utilizing robotics for efficiency. The data from these tests is fed back into the AI models, improving their accuracy.
This enhancement aims to streamline the drug discovery process, benefiting both Exscientia's internal projects and its collaborations, such as those with Sanofi. The integration of AWS's scalable and flexible solutions is expected to transform the biopharma industry by increasing the quality and speed of drug development.
Exscientia announced key leadership appointments to enhance its AI-driven drug design and oncology clinical development. John P. Overington, Ph.D., was named Chief Technology Officer to lead the integration of AI in drug discovery. Overington has over 30 years of bioinformatics experience, including roles at BenevolentAI and Pfizer. Maria-Louise Fjällskog, M.D., Ph.D., was appointed interim Chief Medical Officer to oversee oncology clinical strategies. Fjällskog brings 30 years of oncology expertise, having held positions at Novartis and Faron. The leadership changes aim to maximize AI benefits and refine oncology-focused clinical strategies.
Exscientia (Nasdaq: EXAI) has announced its participation in two significant investor conferences in June 2024. The management will be present at the Barclays Digital and Disruptive Technology Conference on June 11 at 9:45 a.m. BST in London, England. Additionally, they will engage in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11 at 3:20 p.m. EDT (8:20 p.m. BST) in Miami, Florida. Live webcasts of these events will be available on Exscientia's website under the 'Investors & Media' section. Archived replays will be accessible for about 30 days post-presentation.